This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Reducing Reconsolidation of Trauma Memories With Propranolol

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2014 by Alain Brunet, Ph.D., Douglas Mental Health University Institute.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Alain Brunet, Ph.D., Douglas Mental Health University Institute
ClinicalTrials.gov Identifier:
NCT01349439
First received: March 31, 2011
Last updated: June 23, 2014
Last verified: June 2014
March 31, 2011
June 23, 2014
March 2011
January 2015   (Final data collection date for primary outcome measure)
  • Electromyogram [ Time Frame: Two weeks post-treatment ]
  • Heart rate [ Time Frame: Two weeks post-treatment ]
  • Skin conductance [ Time Frame: Two weeks post-treatment ]
Same as current
Complete list of historical versions of study NCT01349439 on ClinicalTrials.gov Archive Site
  • PTSD symptom levels [ Time Frame: 2 to 26 weeks ]
    PTSD symptom levels will be assessed 2 to 26 weeks after randomization
  • Quality of life [ Time Frame: 2 to 26 weeks ]
    Quality of life assessments will be conducted 2 to 26 weeks following randomization
  • Memory Experience [ Time Frame: 2 to 26 weeks ]
    The Memory Experiences Questionnaire will be administered from 2 to 26 weeks following randomization
  • Psychophysiological assessments [ Time Frame: 26 weeks ]
    Psychophysiological assessments will be repeated 26 weeks following randomization
Same as current
Not Provided
Not Provided
 
Reducing Reconsolidation of Trauma Memories With Propranolol
Reduction of the Reconsolidation of the Trauma Memory With Propranolol
The purpose of this study is to test whether propranolol is capable of reducing subsequent physiological trauma-related conditioned responses, as well as self-reported post-traumatic stress disorder (PTSD) symptoms.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Posttraumatic Stress Disorder
  • Drug: Propranolol
    1mg per Kg (participant weight)
  • Drug: Short acting + long acting propranolol + memory reactivation
    After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
  • Experimental: Propranolol + Memory Reactivation
    This arm involves recalling the traumatic event after administration of propranolol
    Intervention: Drug: Propranolol
  • Experimental: Placebo + Memory reactivation
    This arm involves recalling the traumatic event after administration of a placebo
    Intervention: Drug: Propranolol
  • Experimental: Placebo + No Memory Reactivation
    This arm involves administration of a placebo without recalling the traumatic event
    Intervention: Drug: Propranolol
  • Experimental: Propranolol + No Memory Reactivation
    This arm involves administration of propranolol without recalling the traumatic event
    Intervention: Drug: Propranolol
  • Open-label Propranolol + Memory Reactivation
    All participants terminating the double-blind phase of the study will receive open-label reconsolidation blockade treatment with propranolol combined with recall of the traumatic event for six weeks.
    Intervention: Drug: Short acting + long acting propranolol + memory reactivation
Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2008 May;42(6):503-6. Epub 2007 Jun 22.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
76
Not Provided
January 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Suffer from chronic PTSD for at least 6 consecutive months;
  • Obtain a score of 33 or more on the Impact of Events Scale-Revised:
  • For participants aged 40 years: accept to undergo an electrocardiogram assessment. The results of the electrocardiogram must be normal;
  • Accept to not commence taking new medications on a regular basis during the study.

Exclusion Criteria:

  • Hypotension;
  • Cardiac rhythm below 55 beats per minute;
  • Medical conditions that contraindicates the administration of propranolol;
  • Previous adverse reaction to, or non-compliance with, beta-blockers;
  • Current use of medication that may involve potentially dangerous interactions with propranolol;
  • Any medication that can have an impact on cardiac rhythm;
  • Women who are breast feeding;
  • Past or present bipolar disorder or psychosis,
  • Present substance abuse or dependence, suicidal ideation;
  • Participating in psychotherapy other than support psychotherapy;
  • An average score above 20 on the Dissociative Experience Scale.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01349439
08-44
No
Not Provided
Not Provided
Alain Brunet, Ph.D., Douglas Mental Health University Institute
Douglas Mental Health University Institute
Canadian Institutes of Health Research (CIHR)
Principal Investigator: Alain Brunet, Ph.D. Douglas Institute Research Centre
Douglas Mental Health University Institute
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP